The effectiveness and safety of complex treatment of patients with drug-resistant pulmonary tuberculosis using delamanide

Background. In 2020, a new anti-tuberculosis drug, delamanid, was first approved and introduced in Russia for the treatment of drug-resistant TB (DR), and therefore it is interesting to study its effectiveness and safety. The aim. T o evaluat e the efficacy and safety of delamanid-containing chemotherapy regimens in patients with multidrug-resistant tuberculosis as part of complex treatment compared with standard regimens. Methods. A bidirectional cohort study was conducted, including 76 patients with pulmonary tuberculosis with DR TB, divided into two comparable groups. Group 1 included 38 patients in thechemotherapyregimenwhoweretreatedwithdelamanide, the group was recruited prospectively. Group 2 included 38 patients who used chemotherapy regimens without the inclusion of delamanide, the group was recruited retrospectively. R esults. The effec tiveness of treatment of patients with DR TB pulmonary tuberculosis according to the criterion of cessation of bacterial excretion was 27 (79,4 %) people in group 1 against 19 people (51,4 %) in group 2 (p = 6,115, χ2 = 0,024), according to the criterion of elimination of cavities 23 patients (71,9 %) cases against 15 patients (45,5 %), respectively (p = 4,670, χ2 = 0,044). In group 1 of patients, surgical treatment was performed in the early stages of therapy by 2 months – in 9 patients (28,1 %) cases against 3 people (10,3 %) – in group 2, by 4 months – in 12 patients (37,5 %) cases against 5 patients (17,2 %), respectively. There was no statistically significant difference in adverse event frequency between the groups (p > 0,05) Conclusion. The timely use of surgical methods in patients with DR TB of the lungs, combined with the presence of delamanide in the chemotherapy regimen, made it possible to achieve higher treatment effectiveness.